Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. - Wikidata - wikimedia - TriplyDB

Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.

Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.

http://www.wikidata.org/entity/Q43806776

about

Histone methyltransferases: novel targets for tumor and developmental defects Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms Medical treatment of renal cancer: new horizons The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA Molecular genetics of clear-cell renal cell carcinoma VHL, the story of a tumour suppressor gene.miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma Snail heterogeneity in clear cell renal cell carcinoma.Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance Role of several histone lysine methyltransferases in tumor development.Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.Genetic mutations associated with metastatic clear cell renal cell carcinoma.Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.Examining the impact of gene variants on histone lysine methylation New insights on chromatin modifiers and histone post-translational modifications in renal cell tumours.The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.Inhibitors of Protein Methyltransferases and Demethylases.First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation.The long noncoding RNA urothelial carcinoma-associated 1 overexpression as a poor prognostic biomarker in clear cell renal cell carcinoma.Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis.Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.Imaging-genomic pipeline for identifying gene mutations using three-dimensional intra-tumor heterogeneity features.Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1.Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications.Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.BRM/SMARCA2-negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations, deletions and promoter methylation.Serum tissue factor as a biomarker for renal clear cell carcinoma.The epigenetic landscape of clear-cell renal cell carcinoma.

P2860

Q26775027-0A8A1DA0-AF1F-4082-AC7B-6C24345B49C9 Q26785930-EC138BE2-A308-4855-B7FB-AA5F4053BD66 Q28073174-11467B2F-A185-4C39-9E3F-F6BE31F94CE4 Q28083152-FB9040CF-4631-465F-BFD7-303883639619 Q28397229-BD72A76C-4479-4ED7-8626-7568C5E40DB1 Q33709786-D4A87517-8877-41D4-953B-D5A59539908B Q33729097-7EFCEE29-D3D4-4C51-AC0E-5B4C23612A35 Q34455226-84B00D37-0E14-48DB-BE77-6EC8EBE54508 Q35551941-5C4B33FC-D2C8-4FC5-96FD-BF33507A15C8 Q35677757-7561BFE1-3A1E-49D7-9BAE-AD530CC7B7D2 Q35948243-B43BC409-1F42-4014-AE0B-D92D174AB28F Q36105139-04D7E544-B5EB-485C-9EC1-47DE86377705 Q36639797-D5848991-4D0C-469E-93A8-2303BD3426AD Q37016755-D9421D33-D416-43A3-9383-A9E9D8FBED4A Q37085985-08E05BAA-60FB-4022-9BA0-D34917A4FA69 Q37573538-F333275C-9B67-466E-9076-2719A5B75F12 Q38214535-06739556-A9EA-4D1C-A2E8-17378BA406AF Q38294198-6E617D4D-BA5F-4853-B8E8-937327580BF9 Q38419495-EB867E2A-DC06-48EC-9FF9-A1853608350D Q38740496-57A771A2-AFED-4645-AAE6-7817A12AAF3A Q38762066-8D6F1658-B52B-4BC4-8D7E-85841947245D Q38810854-DE508A6B-0E4B-4F6C-8701-BBFFCEDDA5B3 Q38811459-64CE431E-6162-4DD7-9289-DFF1FA9EB786 Q38813611-81DA2BDE-0515-4246-A4E6-01E7FAD7F643 Q38843978-A00F4F39-055C-4EAB-9ABA-275A51482488 Q38910995-FCAA9B35-AD68-41DF-BEDC-3C1B8F29BE3F Q39118911-FA39AFAA-A21B-47C0-95B3-A3AB3C9A8098 Q39608223-2FE0BAD0-454F-4904-AAE8-85E252C3BD46 Q40028818-DD5CFAA2-F577-430F-9316-40DC01C0D3DD Q40243097-A9739A8C-BFB6-45E5-A40C-7CBE0C23D776 Q41242139-3BE0AF4D-3238-4AC5-969C-54ACDEC2771C Q41574276-D88586D1-9E93-4EF3-B0D0-8EC25E1E1504 Q41882621-A4CA9C5D-BC00-4031-A95C-5C9EA8C9D9D3 Q42737907-AE458600-6656-43EC-B5DC-8512A2B0EA01 Q46856592-3D7B3D1E-FD60-4515-B319-C2109668D36C Q47592158-2B2FDC73-7D51-4DDA-B73B-C143F248C5A4 Q47972869-E4D332A5-D613-479B-A9EB-1E03309EB2BA Q48368561-B43149DD-8545-44BB-BA59-6E2C5BA40896 Q50323362-52588EF4-14CB-441B-B88D-BD0D982DA478 Q51091490-6206FC38-C951-48D5-9DE0-C14D40F0F726

P2860

Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.

http://www.wikidata.org/entity/Q43806776

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Clinical and pathological impa ...... ear cell renal cell carcinoma.

@en

Clinical and pathological impa ...... ear cell renal cell carcinoma.

@nl

type

label

Clinical and pathological impa ...... ear cell renal cell carcinoma.

@en

Clinical and pathological impa ...... ear cell renal cell carcinoma.

@nl

prefLabel

Clinical and pathological impa ...... ear cell renal cell carcinoma.

@en

Clinical and pathological impa ...... ear cell renal cell carcinoma.

@nl

P1433

Q43806776-360F2E16-C360-4403-9BB8-A48B6560376D

P1476

Q43806776-1690C3D3-719E-4931-B1B5-4E19C9FCD3D7

P2093

Q43806776-011FD7AD-DD84-4A19-884D-187A0B11925C

Q43806776-0B5C4A2C-FC10-474E-82B2-10045A646A97

Q43806776-0D47C26A-5199-450E-878E-0C9F734C3081

Q43806776-30839A28-8D82-4912-B0A9-95B8BCD6CAEE

Q43806776-5335FB34-38A8-4B71-B36C-BF0222C40C31

Q43806776-54E46D31-850B-4BE7-B12F-9BD6006F8B69

Q43806776-5FD69554-0A5D-4678-AAAB-BC880C4CF6D0

Q43806776-7FD81515-4E08-4BCE-A1A3-08205C9202D2

Q43806776-A8D26466-CBEE-4B9C-B5A0-8133F8D88F01

Q43806776-EB3E9C3D-2D66-47FC-A79A-FC5F36851C9D

P2860

Q43806776-004068F1-28FE-47B1-A9EF-3571E2D3473D

Q43806776-040924A4-7D25-4A01-BE30-F2E23EB61AB0

Q43806776-0A8DC0E6-631C-429D-ADDA-724F28F7AC8A

Q43806776-0CD2C734-4F8F-4A90-9C5B-CE65DB35C6F9

Q43806776-10CD29CE-34C5-4E96-92C4-DEA3AD54648F

Q43806776-14B950A9-05B3-4452-9CB4-404247FC62D4

Q43806776-14F43D7B-2124-4C1B-B560-F6681A41F2BE

Q43806776-198ADE65-D441-44C3-B2DF-1F0B8ABCA10F

Q43806776-1C7E2063-ABED-4936-B730-F44BE8EF4306

Q43806776-1FE8C6E0-D3B3-4DB8-A917-8F37F9FE0AF7

P304

Q43806776-2BF8456B-8238-4E4A-B104-DF6110669CCC

P31

Q43806776-8D08CE77-2A4A-4326-AF75-FC24FFE590C7

P356

Q43806776-E5C4A1E0-E651-43A8-B4ED-79A0EBA84CE5

P433

Q43806776-2AB002BB-B6DF-442B-A304-2E579155377A

P478

Q43806776-ABCA1071-75ED-4922-AAE7-16D3EC8D21CF

P50

Q43806776-0E922C46-B9AE-4176-AE32-C7CB9E238ABF

Q43806776-1A203CE7-7FDF-4802-9132-E003B64B29A0

Q43806776-5539E545-EC0A-48EF-A38D-28777D86FBCD

P577

Q43806776-319C08A1-3143-4BE4-9A19-A6F2A91F2B7D

P5875

Q43806776-34C989E0-B07F-476B-9EF4-B2D20D978C83

P698

Q43806776-B93B1F9E-FF57-4B33-AA7E-DFAFCB23981F

P356

P1433

Genes, Chromosomes and Cancer

P1476

Clinical and pathological impa ...... lear cell renal cell carcinoma

@en

P2093

Andreas Claas

http://www.w3.org/2001/XMLSchema#string

Andrew Dunham

http://www.w3.org/2001/XMLSchema#string

Andrew F Slatter

http://www.w3.org/2001/XMLSchema#string

Andrew P May

http://www.w3.org/2001/XMLSchema#string

Anne Warren

http://www.w3.org/2001/XMLSchema#string

Beverley Haynes

http://www.w3.org/2001/XMLSchema#string

Conrad P Lichtenstein

http://www.w3.org/2001/XMLSchema#string

Ian Roberts

http://www.w3.org/2001/XMLSchema#string

Lucy Gossage

http://www.w3.org/2001/XMLSchema#string

Nitzan Rosenfeld

http://www.w3.org/2001/XMLSchema#string

P2860

Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB

BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity

The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1.

Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1

BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

Frequent mutation of BAP1 in metastasizing uveal melanomas

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands

P304

38-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/GCC.22116

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Muhammed Murtaza

Francesco Marass

P577

2013-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258117181

http://www.w3.org/2001/XMLSchema#string

P698

24166983

http://www.w3.org/2001/XMLSchema#string